Novartis has just posted a better-than-expected increase in global sales of 12% growth in 2024, and US revenue growth was its biggest driver. The boost came in the company’s first full year as a ‘pure play’ big pharma company, and the Swiss firm believes it has already demonstrated the benefits of its more streamlined business, with greater co-ordination between R&D and commercial divisions.
Novartis’s Bulto: Kisqali Is Blueprint For More Competitive US Launches
Novartis enjoyed exceptional growth in 2024, and its US leader, Victor Bulto, puts that down to greater R&D and commercial co-ordination paying off with drugs such as Kisqali in early breast cancer.
